What Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, CAMP4 THERAPEUTICS CORPORATION's intrinsic value is estimated at $1.41, suggesting the stock is overvalued at its current price of $4.45. With 9 out of 9 models flagging downside (-68.3% average return), the market may be pricing in unsustainable growth. Notably, FTNN sees the most upside at -28.2% (fair value: $3.20), while Bayesian DCF is the most conservative at -89.4% ($0.47). The spread between these extremes — +61.3% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About CAMP?
9 of 13 models are currently active for CAMP. All 9 active models suggest the stock trades above fair value. The Bayesian DCF estimates CAMP's intrinsic value at $0.47, implying -89.4% downside from the current price. See which stocks rank higher →
How Does CAMP Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, CAMP ranks #86 by Quality of Company score. CirclFi's QOC score of 6.6/10 evaluates 32 fundamental signals. A score of 6.6 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
Within the Pharmaceutical Preparations space, CAMP4 THERAPEUTICS CORPORATION competes in an environment where FDA approval probability often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is CAMP a Value Trap?
CirclFi's Value Trap algorithm assigns CAMP a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for CAMP4 THERAPEUTICS CORPORATION. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, CAMP4 THERAPEUTICS CORPORATION is rated at 6.6/10. This solid-tier score maintains reasonable quality metrics with some areas for improvement.
The gap between the most bullish and bearish model spans +61.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every CAMP valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across CAMP's 9 active models, average confidence is 22%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad